Prosecution Insights
Last updated: November 04, 2026
Application No. 18/653,960

HEXAPEPTIDE DERIVATIVE AND COSMETIC COMPOSITION OR PHARMACEUTICAL COMPOSITION AND USE THEREOF

Non-Final OA §101§102§103§112
Filed
May 02, 2024
Priority
Nov 04, 2021 — continuation of PCTCN2021128560
Examiner
BRADLEY, CHRISTINA
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shenzhen Winkey Technology Co. Ltd.
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
2m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
651 granted / 1040 resolved
+2.6% vs TC avg
Strong +33% interview lift
Without
With
+33.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
63 currently pending
Career history
1111
Total Applications
across all art units

Statute-Specific Performance

§101
6.0%
-34.0% vs TC avg
§103
28.9%
-11.1% vs TC avg
§102
21.5%
-18.5% vs TC avg
§112
24.0%
-16.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1040 resolved cases

Office Action

§101 §102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 101/112 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7-12 are rejected under 35 U.S.C. 101 because the claimed invention is directed to nonstatutory subject matter. The claims do not fall within at least one of the four categories of patent eligible subject matter because they recite a “use” rather than a proper process with any active, positive steps delimiting how this use is actually practiced. See MPEP § 2173.05(q). Claims 7-12 are rejected under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The instant claims merely recite a use without any active, positive steps delimiting how this use is actually practiced. See MPEP § 2173.05(q). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-6 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by KR20190133976A (published 04 Dec 2019; machine translation to English obtained from Google patents). KR20190133976A teaches (formula 5 on p. 6 of the translation): PNG media_image1.png 227 483 media_image1.png Greyscale which is a peptide derivative of instant Formula (I) wherein R1 is CA-, R2 is -OR3, and R3 is H. Therefore, KR20190133976A anticipates claims 1-2. Regarding claim 3, the compound is identical to instant peptide derivative (1). Regarding claim 4, KR20190133976A teaches that the peptide derivative has a collagen production, MMP-1 inhibitory, skin elasticity, and wrinkle improvement effects, which make it suitable for use as an active ingredient in a cosmetic composition. The cosmetic composition comprising the peptide derivative and components commonly added thereto, such as conventional auxiliaries and carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings (p. 6 of the translation):. Regarding claims 5-6, KR20190133976A teaches that the cosmetic composition contains an effective amount of the peptide derivative and may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, and oils (p. 6 of the translation). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-6 are rejected under 35 U.S.C. 103 as being unpatentable over US 2004/0142873 A1 in view of US 2014/056835 A1, US 2010/261879 A1, and WO 2013/042811 A1. US 2004/0142873 A1 teaches a cosmetic or dermatological composition comprising an effective amount of the peptide (Gly-Pro-Gln)2NH2, to promote adhesion between skin cells, promote cell adhesion, to treat and prevent the symptoms of skin aging and solar exposure, and to enhance skin appearance. US 2004/0142873 A1 teaches that the peptide may be acylated or acetylated at the N-terminus. US 2004/0142873 A1 teaches that the cosmetic composition further comprising adjuvants, such as solvents, thickeners, thinners, antioxidants, dyestuffs, screening agents, pigments, fillers, preservatives, perfumes or odor absorbers. US 2004/0142873 A1 teaches that the composition can be a cream, a water-in-oil or oil-in-water emulsion, a multiple emulsion, a solution, a suspension, a powder, a cream, a lotion, a milk, a serum, a pomade, a gel, a paste or a foam (see abstract, claims 1-9, and description, paragraphs [0046]-[0048]). US 2004/0142873 A1 does not teach that the peptide (Gly-Pro-Gln)2NH2 is connected to caffeic acid or gallic acid at the N-terminus. It is within the ordinary skill in the art to modify peptides having cosmetic and dermatological activity with caffeic acid and gallic acid. For example, US 2014/056835 A1 discloses a composition for skin whitening, comprising a small molecule-peptide conjugate, such as caffeic acid-LG-NH₂; the composition further comprises oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelation agents, colorants, preservatives, and perfumes (see abstract, claims 1-5, and preparation embodiment 1). WO 2013/042811 A1 also teaches a cosmetic composition comprising an active peptide conjugated to caffeic acid, specifically the alpha-neoendorphin peptide with anti-itch activity (abstract). In addition, US 2010/261879 A1 discloses peptide derivatives, the structure thereof being galloyl-tetrapeptide, and provided with improved free radical scavenging activities and excellent anti-oxidative activities (see embodiments, comparative examples, and test examples). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the peptide (Gly-Pro-Gln)2NH2 taught by US 2004/0142873 A1 by conjugating it to caffeic acid or gallic acid at the N-terminus according to the prior art of US 2014/056835 A1, US 2010/261879 A1 and WO 2013/042811 A1. The rationale for obviousness is combining prior art elements according to known methods to yield predictable results (MPEP § 2143.01(A)). The relevant findings for this rationale are as follows. (1) The prior art included each element claimed, although not necessarily in a single prior art reference, with the only difference between the claimed invention and the prior art being the lack of actual combination of the elements in a single prior art reference. In the instant case, the only difference between the claimed invention and the primary reference the caffeic acid or gallic acid conjugated to the N-terminus of the peptide. This difference is found in the prior art of US 2014/056835 A1, US 2010/261879 A1, and WO 2013/042811 A1, which teach that peptides having cosmetic and dermatological activity can be conjugated at the N-terminus with caffeic acid and gallic acid. Therefore, the only difference between the claimed invention and the prior art is the actual combination of elements in a single prior art reference. (2) One of ordinary skill in the art could have combined the elements as claimed by known methods, and that in combination, each element merely performs the same function as it does separately. One of ordinary skill in the art could have combined the caffeic acid and gallic acid taught by US 2014/056835 A1, US 2010/261879 A1, and WO 2013/042811 A1 with the cosmetic peptide (Gly-Pro-Gln)2NH2 taught by US 2004/0142873 A1 using the known method of conjugating these molecules to peptides taught by US 2014/056835 A1, US 2010/261879 A1, and WO 2013/042811 A1 (see Example 1 of each). One of ordinary skill in the art would expect that the (Gly-Pro-Gln)2NH2 peptide performs the function of promoting adhesion between skin cells, promoting cell adhesion, treating and preventing the symptoms of skin aging and solar exposure, and enhancing skin appearance in the combination, which is the same function it performs separate from the combination. Likewise, one of ordinary skill in the art would expect that caffeic acid and gallic acid each perform the function of enhancing skin appearance in the combination, which is the same function they perform separate from the combination. Therefore, one of ordinary skill in the art could have combined the elements as claimed by known methods, and that in combination, each element merely performs the same function as it does separately. (3) One of ordinary skill in the art would have recognized that the results of the combination were predictable. One of ordinary skill in the art would expect that the caffeic acid and gallic acid would perform the function of enhancing skin appearance in the combination because the prior art demonstrates this function when these compounds are attached to other cosmetic peptides. Therefore, one of ordinary skill in the art would have recognized that the results of the combination were predictable. (4) Whatever additional findings based on the Graham factual inquiries may be necessary, in view of the facts of the case under consideration, to explain a conclusion of obviousness. The data in the specification is consistent with, not unexpected in view of the cited art. The rationale to support a conclusion that the claim would have been obvious is that all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination yielded nothing more than predictable results to one of ordinary skill in the art. KSR, 550 U.S. at 416, 82 USPQ2d at 1395; B/E Aerospace, Inc. v. C&D Zodiac, Inc., 962 F.3d 1373, 1379, 2020 USPQ2d 10706 (Fed. Cir. 2020); Sakraida v. AG Pro, Inc., 425 U.S. 273, 282, 189 USPQ 449, 453 (1976); Anderson’s-Black Rock, Inc. v. Pavement Salvage Co., 396 U.S. 57, 62-63, 163 USPQ 673, 675 (1969); Great Atl. & P. Tea Co. v. Supermarket Equip. Corp., 340 U.S. 147, 152, 87 USPQ 303, 306 (1950). "[I]t can be important to identify a reason that would have prompted a person of ordinary skill in the relevant field to combine the elements in the way the claimed new invention does." KSR, 550 U.S. at 418, 82 USPQ2d at 1396. Therefore, claims 1-3 are obvious over the cited art. Regarding claims 4-6, US 2004/0142873 A1 teaches a cosmetic or dermatological composition comprising an effective amount of the peptide further comprising adjuvants, such as solvents, thickeners, thinners, antioxidants, dyestuffs, screening agents, pigments, fillers, preservatives, perfumes or odor absorbers. US 2004/0142873 A1 teaches that the composition can be a cream, a water-in-oil or oil-in-water emulsion, a multiple emulsion, a solution, a suspension, a powder, a cream, a lotion, a milk, a serum, a pomade, a gel, a paste or a foam (see abstract, claims 1-9, and description, paragraphs [0046]-[0048]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINA M MARCHETTI BRADLEY whose telephone number is (571)272-9044. The examiner can normally be reached Monday-Friday, 8:30 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko G Garyu can be reached at (571) 270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CHRISTINA M MARCHETTI BRADLEY Primary Examiner Art Unit 1654 /CHRISTINA M MARCHETTI BRADLEY/ Primary Examiner, Art Unit 1654
Read full office action

Prosecution Timeline

May 02, 2024
Application Filed
Sep 23, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779017
EXENATIDE ANALOG
4y 7m to grant Granted Nov 03, 2026
Patent 12780893
CONFORMATIONALLY CONSTRAINED GLUCAGON ANALOGUES AND THEIR USE IN GLUCAGON-SINGLE CHAIN INSULIN FUSION PROTEINS
3y 2m to grant Granted Nov 03, 2026
Patent 12779012
KEAP1/NRF2 PROTEIN-LIKE POLYMERS
3y 1m to grant Granted Nov 03, 2026
Patent 12760067
PEPTIDES FOR USE IN SKIN AND HAIR PIGMENTATION
3y 5m to grant Granted Oct 13, 2026
Patent 12758482
COMPOSITIONS AND METHODS RELATING TO STIMULATION OF HYALURONIC ACID
3y 6m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
96%
With Interview (+33.3%)
2y 8m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1040 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month